Login / Signup

Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey.

Bjorn EliassonJan EkelundRikard AmberntssonMervete MiftarajAnn-Marie Svensson
Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2019)
Boehringer Ingelheim AB, Sweden.
Keyphrases
  • cardiovascular disease
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • type diabetes
  • patient reported outcomes
  • combination therapy
  • smoking cessation